Profile data is unavailable for this security.
About the company
Zhejiang Shouxiangu Pharmaceutical Co Ltd is a China-based company principally engaged in the breeding, cultivation, processing and sales of traditional Chinese medicinal materials, such as the ganoderma lucidums and dendrobium officinales. The Company's main products include ganoderma lucidum spore powder, Tiepi Fengdou granule, ganoderma extract products and fresh dendrobium officinales, among others. The Company mainly operates its businesses in domestic markets through wholesaling and direct sales.
- Revenue in CNY (TTM)799.09m
- Net income in CNY269.00m
- Incorporated1997
- Employees1.14k
- LocationZhejiang Shouxiangu Pharmaceutical Co LtdNo. 12 Huanglong 3rd Road, Wuyi CountyJINHUA 321200ChinaCHN
- Phone+86 57 987622285
- Fax+86 57 987621769
- Websitehttp://www.sxg1909.com/
More ▼
Mergers & acquisitions
| Acquired company | 603896:SHH since announced | Transaction value |
|---|---|---|
| Hangzhou Yunhe Hengli Commercial Real Estate Co Ltd | -27.80% | 30.28m |
Data delayed at least 15 minutes, as of May 17 2024.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Hile Bio-Technology Co Ltd | 239.79m | 44.92m | 5.24bn | 295.00 | 118.98 | 4.19 | -- | 21.84 | 0.0669 | 0.0669 | 0.3664 | 1.90 | 0.154 | 1.06 | 2.40 | 812,857.50 | 2.06 | 1.73 | 2.56 | 2.47 | 45.19 | 50.44 | 13.37 | 10.37 | 1.16 | -- | 0.0562 | 23.89 | -19.76 | -1.11 | -48.30 | 24.17 | -41.32 | 23.47 |
| Hunan Fangsheng Pharmaceutical Co Ltd | 1.63bn | 193.23m | 5.33bn | 1.69k | 27.37 | 3.47 | -- | 3.27 | 0.4428 | 0.4428 | 3.72 | 3.49 | 0.5227 | 1.48 | 6.56 | 966,866.90 | 5.93 | 5.39 | 9.72 | 9.37 | 67.75 | 66.91 | 11.34 | 8.95 | 0.5527 | 16.41 | 0.3447 | 46.47 | -9.12 | 9.15 | -34.64 | 20.68 | 23.91 | 4.75 |
| InventisBio Co Ltd | 194.13m | -249.28m | 5.41bn | 221.00 | -- | 2.80 | -- | 27.89 | -0.4289 | -0.4289 | 0.3348 | 3.35 | 0.0898 | -- | 1.96 | 878,429.50 | -11.53 | -- | -12.26 | -- | 97.85 | -- | -128.41 | -- | -- | -- | 0.0054 | -- | -- | -- | 41.26 | -- | -- | -- |
| Innovita Biological Technology Co Ltd | 625.12m | 266.22m | 5.63bn | 404.00 | 21.15 | 2.83 | -- | 9.01 | 1.96 | 1.96 | 4.59 | 14.62 | 0.3093 | 1.67 | 6.23 | 1,547,324.00 | 13.17 | -- | 14.20 | -- | 80.99 | -- | 42.59 | -- | 10.66 | -- | 0.0015 | -- | 7.03 | -- | 15.44 | -- | -- | -- |
| Zhejiang Shouxiangu Pharmaceuticl Co Ltd | 799.09m | 269.00m | 5.70bn | 1.14k | 20.55 | 2.46 | -- | 7.14 | 1.37 | 1.37 | 4.08 | 11.49 | 0.2573 | 0.9016 | 6.83 | 699,118.90 | 8.66 | 10.04 | 10.48 | 11.63 | 81.31 | 83.66 | 33.66 | 28.29 | 3.33 | -- | 0.2547 | 47.86 | -5.39 | 8.93 | -8.39 | 18.78 | 12.23 | 17.13 |
| Beijing Sun-Novo Pharma Research Co Ltd | 951.95m | 209.57m | 5.91bn | 1.37k | 28.19 | 5.82 | -- | 6.21 | 1.87 | 1.87 | 8.50 | 9.06 | 0.5465 | 26.19 | 1.77 | 694,854.30 | 11.70 | 12.99 | 19.13 | 21.70 | 59.10 | 53.93 | 21.40 | 21.34 | 1.77 | 45.00 | 0.3721 | 10.74 | 37.76 | 47.22 | 18.08 | 54.90 | 34.77 | -- |
| Sichuan Huiyu Pharmaceutical Co Ltd | 931.96m | 147.83m | 5.91bn | 1.36k | 40.00 | 1.55 | -- | 6.35 | 0.349 | 0.349 | 2.20 | 9.01 | 0.2032 | 0.9121 | 14.88 | 683,254.60 | 3.18 | 10.41 | 3.82 | 12.76 | 84.46 | 89.89 | 15.65 | 21.42 | 2.92 | -- | 0.1299 | 20.54 | -37.92 | 76.37 | -43.86 | -- | 66.72 | -- |
| Shanghai Yizhong Pharmaceutical Co Ltd | 336.56m | 135.71m | 5.96bn | 43.00 | 43.89 | 3.98 | -- | 17.71 | 0.858 | 0.858 | 2.13 | 9.47 | 0.2219 | 0.9416 | 3.28 | 7,826,913.00 | 8.95 | -0.9181 | 9.39 | -0.9485 | 93.54 | 93.19 | 40.32 | -6.11 | 12.66 | -- | 0.0342 | -- | 52.68 | -- | 13.09 | -- | 20.44 | -- |
Data as of May 17 2024. Currency figures normalised to Zhejiang Shouxiangu Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
21.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2023 | 15.91m | 8.07% |
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2023 | 8.47m | 4.29% |
| Huashang Fund Management Co., Ltd.as of 30 Jun 2023 | 4.18m | 2.12% |
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 2023 | 2.85m | 1.44% |
| Orient Securities Asset Management Co. Ltd.as of 30 Jun 2023 | 2.36m | 1.20% |
| Cinda Fund Management Co. Ltd.as of 30 Jun 2023 | 2.19m | 1.11% |
| GF Fund Management Co., Ltd.as of 30 Jun 2023 | 1.83m | 0.93% |
| First Seafront Fund Management Co., Ltd.as of 30 Jun 2023 | 1.60m | 0.81% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2023 | 1.18m | 0.60% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2023 | 864.46k | 0.44% |
More ▼
Data from 30 Jun 2023 - 30 Jun 2023Source: FactSet Research Systems Inc.
